Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS, page-4

Interesting - up to 30 sites now so 10 patients each maybe  ?   .... and that is only an average of 3 patients per site (30 x 3) to reach the first "interim analysis" ... GLTAH

The trial will include up to 30 sites across North America, with patient screening and enrollment having already commenced at Baylor University Medical Center, a part of Baylor Scott & White Health; Cleveland Clinic, Duke University Hospital, Keck Medical Center of USC, Lutheran Hospital Indiana, The Mount Sinai Hospital, Ochsner Medical Center – Jefferson Highway, and the University of Maryland School of Medicine/University of Maryland Medical Center. Enrollment is expected to complete within three to four months, with interim analyses planned which could result in stopping the trial early for efficacy or futility.